Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pristimerin Suppresses Janus Kinase/Signal Transducers and Activators of Transcription Oncogenic Signaling To Drive Mitochondrial and Caspase-Dependent Apoptosis in Multiple Myeloma.

ACS pharmacology & translational science·2026
Same author

Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.

Cancer reports (Hoboken, N.J.)·2026
Same author

Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure.

Journal of translational medicine·2026
Same author

Predicting Metastatic Potential from Histopathological Whole Slide Images of Primary Tumors in Head and Neck Squamous Cell Carcinoma Using Attention-Based Deep Learning and Signaling Pathway Alterations.

Head and neck pathology·2026
Same author

Integrated transcriptomic and functional characterization of Claudin-1 reveals its oncogenic and immunomodulatory roles in pancreatic ductal adenocarcinoma.

Tissue barriers·2026
Same author

Sanguinarine Induces ROS-Mediated Mitochondrial Dysfunction and Inhibits AKT/GSK3 Signaling to Potentiate Apoptotic Effects in Cutaneous T-Cell Lymphoma.

Phytotherapy research : PTR·2026

Related Experiment Video

Updated: May 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Synthetic immunomodulators: Revolutionizing immunotherapy.

Anju Surendranath1, Adna Mohammed Adan1, Alanoud Abdulla1

  • 1Metabolic and Mendelian Disorders Clinical Research Program and Precision OMICs Research & Translational Science, Sidra Medicine, Doha, Qatar.

Advances in Protein Chemistry and Structural Biology
|May 14, 2026
PubMed
Summary

Synthetic immunomodulators offer precise immune control, overcoming limitations of traditional therapies. These engineered agents enhance antitumor responses and manage inflammation with improved timing and targeting for better patient outcomes.

Keywords:
Cancer immunotherapySynthetic immunomodulatorsTumor microenvironment

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: May 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

  • Immunology and Medicine
  • Synthetic Biology
  • Nanotechnology

Background:

  • Immunotherapy, while transformative in oncology, faces challenges like patient response variability, treatment resistance, and immune-related toxicities.
  • Classical immunomodulation often resulted in broad, toxic effects, necessitating more refined approaches.
  • Advances in chemistry, synthetic biology, and nanotechnology enable the development of precisely engineered immunomodulatory agents.

Purpose of the Study:

  • To explore synthetic immunomodulators as a means to achieve tighter control over immune activity.
  • To categorize synthetic immunomodulators and discuss their therapeutic applications in strengthening immunity and reducing inflammation.
  • To highlight clinical applications, translational challenges, and future directions for synthetic immunomodulators.

Main Methods:

  • Review and categorization of synthetic immunomodulators into classes: small molecules, synthetic peptides/peptidomimetics, cytokine mimetics, nucleic acid-based modulators, and synthetic checkpoint modulators.
  • Analysis of therapeutic use cases, including vaccine adjuvants, tumor microenvironment reprogramming, and combination therapies.
  • Summary of clinical translation, focusing on delivery, biodistribution, toxicity, and biomarker-guided patient selection.

Main Results:

  • Synthetic immunomodulators allow for more selective immune tuning compared to broad immunosuppressants or older biologics.
  • These agents can be utilized to either boost protective immunity (e.g., antitumor) or dampen harmful inflammation in autoimmune/inflammatory conditions.
  • Key applications include enhancing vaccine efficacy, overcoming tumor-induced immune suppression, and supporting cytotoxic T cell responses.

Conclusions:

  • Synthetic immunomodulators represent a shift towards precise immune modulation, offering control over timing, location, and cell-type specificity.
  • Translational bottlenecks include optimizing delivery, managing potential overactivation toxicities, and establishing robust biomarker strategies for patient stratification.
  • Monitoring tools like interferon response signatures and immune cell population shifts are crucial for tracking therapeutic efficacy in patients.